Precision for Medicine, which supports “next-generation approaches to drug development and commercialization,” is acquiring Precision Health Economics (PHE).
Headquartered in Los Angeles, CA – PHE is the health economics consultancy and analytics firm, which leverages the expertise of policy analysts, economists, clinicians and academics to advance research on the most complex healthcare questions. Life sciences companies and policymakers around the world turn to PHE to shape strategy, inform key healthcare decisions, and produce changes in policy through research.
Founded by Drs. Dana Goldman, Darius Lakdawalla, and Tomas Philipson, professors at the University of Southern California and the University of Chicago – PHE’s network of academic experts includes numerous nationally and globally recognized scholars in health economics, medicine, and health policy. The team also includes former leaders at the Centers for Medicare and Medicaid Services, the FDA, the Department of the Treasury, the Congressional Budget Office, and the President’s Council of Economic Advisers.
PHE’s network of academic experts includes numerous nationally and globally recognized scholars in health economics, medicine and health policy.“Adding PHE’s differentiated capabilities fortifies our approach to helping life sciences companies deliver more effective treatments to patients in the era of precision medicine by integrating research, analytics, science, and communications,” said Ethan Leder, chairman, Precision for Medicine. “The PHE management team will remain in place and will continue to focus on their customers in the pharmaceutical and life sciences markets.”
The acquisition will expand the existing health economics and outcomes research (HEOR) capabilities of Precision for Value, a business unit of Precision for Medicine. Said unit helps pharmaceutical and life sciences companies demonstrate and communicate the value of innovative medications. Furthermore, the acquisition extends Precision for Medicine’s leadership in HEOR with a focus on innovative approaches to evidence generation.